Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Abstract This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Compl...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N. Beasley, Nishi Rampal, James F. Howard
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2023-06-01
Edice:	Neurology and Therapy
Témata:	Anti-AChR antibody Complement Monoclonal antibody Myasthenia gravis Ravulizumab Patient-centered outcomes
On-line přístup:	https://doi.org/10.1007/s40120-023-00514-4
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!